The company said that it will continue to trade under the symbol “OFIX” and that there will be no changes to its shares, according to the SEC filing.
Orthofix said it expects the domestication move will be effective as of August 1, according to the filing.
In June, Orthofix said that it’s planning a pivot to the spine and extremities market beginning next year, folding its biostim and biologics businesses back into the spine segment five years after it split them out in the first place.
Early rates for DeviceTalks Boston end August 15th.
Don't miss the chance to save $100 and join top medtech innovators including leaders from Hologic, Google, Gray Matter, TransEnterix, NxStage Medical, Smith & Nephew, HeartFlow, Dynatronics, Johnson & Johnson, Allied Minds, and many more.
View Full Agenda
Register today to save. Use code LASTCALL to save an additional 10%.